Cosmos Health's Cosmofarm Sees 20% Customer Growth in 2025
Cosmos Health announced continued operational growth and infrastructure expansion at Cosmofarm, its pharmaceutical distribution subsidiary in Greece. "During 2025, Cosmofarm added nearly 100 new pharmacy customers, representing a weighted average increase of approximately 20% in its active customer base. This growth was accompanied by improved unit economics, with annual revenue per customer increasing by approximately 12% and profitability per customer improving by approximately 14%, driven by enhanced route density, optimized order execution, and increasing operational leverage. Based on current onboarding activity and demand trends, management expects customer growth in 2026 to continue at similar or higher rates. To further strengthen service quality and last-mile delivery performance, Cosmofarm introduced three new delivery routes within the Attica region, expanding geographic coverage and delivery frequency across one of Greece's most densely populated pharmaceutical markets. Cosmofarm's operating model is supported by multi-year, multi-million investments in automation and logistics infrastructure, including advanced ROWA and A-frame robotic systems for procurement, inventory management, and order fulfillment. A further capital investment program of approximately $1 million is currently underway, continuing prior initiatives to expand robotic capacity and throughput... the master plan of the expanded ROWA and A-frame robotic picking line, highlighting an integrated automation layout designed to materially increase processing capacity, enhance accuracy and speed, and support incremental annual revenue potential of approximately $40 million through expanded distribution capability," the company stated.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on COSM
About COSM
About the author
YYAI Director Hongyu Zhou Acquires 4.215M Shares at $1.37, Totaling $5.77M
- YYAI Large Transaction: Director Hongyu Zhou purchased 4.215 million shares of YYAI on Wednesday at $1.37 each, totaling an investment of $5.77 million, reflecting confidence in the company's future and contributing to a 15% increase in stock price on Friday.
- Investment History: Over the past twelve months, Zhou has made three purchases of YYAI shares, totaling $1.86 million at an average cost of $1.29 per share, indicating a sustained positive outlook on the company.
- Cosmos Health Insider Trading: CEO Grigorios Siokas bought 353,321 shares of COSM on Tuesday at $0.50 each, totaling $175,000, which reflects recognition of the company's value, even as the stock rose only 0.7% on Friday.
- Siokas' Investment History: Siokas has made 26 purchases of COSM shares over the past year, totaling $1.93 million at an average cost of $0.45 per share, demonstrating confidence in the company's long-term growth potential.
Cosmos Health Inc. (COSM) Receives Zacks Coverage with $4.50 Price Target
- Coverage Initiation: Zacks Small-Cap Research initiated coverage on Cosmos Health on January 13, 2026, assigning a $4.50 per share valuation, reflecting the company's diversified revenue base and improving financial performance.
- Revenue Growth Outlook: Zacks projects Cosmos Health's revenues to grow from approximately $64.4 million in 2025 to $98.6 million in 2026, with expectations of exceeding $130 million by 2027, driven by higher-margin pharmaceuticals and nutraceuticals.
- U.S. Market Expansion: The report highlights Cosmos Health's entry into the U.S. market through the acquisition of ZipDoctor, a telehealth platform, and the launch of Sky Premium Life in the U.S. nutraceutical market, enhancing its competitive position.
- Advancing R&D Pipeline: Zacks notes Cosmos Health's ongoing development programs targeting obesity and multiple sclerosis, reflecting the company's strategic focus on addressing large disease markets and driving innovation in drug repurposing.
